Literature DB >> 1651524

Intraperitoneal hemorrhage from hepatocellular carcinoma: emergency chemoembolization or embolization.

M Okazaki1, H Higashihara, F Koganemaru, T Nakamura, H Kitsuki, T Hoashi, M Makuuchi.   

Abstract

From 1982 to 1990, 38 patients with intraperitoneal hemorrhage from hepatocellular carcinoma (HCC) underwent treatment with emergency embolization with or without anticancer drug and iodized oil. Before emergency embolization, 24 patients had a serum total bilirubin value of 3.0 mg/dL or less (group A) and 14 patients had hyperbilirubinemia, with a serum bilirubin level greater than 3.0 mg/dL (group B). Successful hemostasis was achieved in all patients. The mean length of survival was 165 days in group A and 13 days in group B. A significant correlation (P less than .00003) between serum bilirubin level and prognosis was obtained. While tumor thrombus in the portal vein made the prognosis poor, there was no significant difference in prognosis between groups with and without tumor thrombus (P = .145). Emergency embolization is an effective treatment in patients with intraperitoneal hemorrhage from HCC. The prognosis for patients with HCC depends on the serum bilirubin level before embolization.

Entities:  

Mesh:

Year:  1991        PMID: 1651524     DOI: 10.1148/radiology.180.3.1651524

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  19 in total

1.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

2.  Superior phrenic artery: an anatomic study.

Authors:  Marios Loukas; Robert G Louis; Christopher T Wartmann; R Shane Tubbs; Ehsan Esmaeili; Allyson C Bagenholm; William Merbs; Brian Curry; Robert Jordan
Journal:  Surg Radiol Anat       Date:  2006-12-20       Impact factor: 1.246

3.  Hemoperitoneum as a first manifestation of hepatocellular carcinoma in western patients with liver cirrhosis: effectiveness of emergency treatment with transcatheter arterial embolization.

Authors:  L Castells; M Moreiras; S Quiroga; A Alvarez-Castells; A Segarra; R Esteban; J Guardia
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 4.  Rupture of Hepatocellular Carcinoma: A Review of Literature.

Authors:  Srimanta K Sahu; Yogesh K Chawla; Radha K Dhiman; Virendra Singh; Ajay Duseja; Sunil Taneja; Naveen Kalra; Ujjwal Gorsi
Journal:  J Clin Exp Hepatol       Date:  2018-04-26

5.  Multidisciplinary management of ruptured hepatocellular carcinoma.

Authors:  Andrzej K Buczkowski; Peter T W Kim; Stephen G Ho; David F Schaeffer; Sung I Lee; David A Owen; Alan H Weiss; Stephen W Chung; Charles H Scudamore
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

6.  Massive bleeding of ruptured metastatic hepatic melanoma treated by transarterial embolization.

Authors:  Ho Jong Chun; Keigo Osuga; Markus Fahrni; Hironobu Nakamura
Journal:  Jpn J Radiol       Date:  2010-06-30       Impact factor: 2.374

7.  Gelatin sponge microparticles for the treatment of the spontaneous rupture of hepatocellular carcinoma hemorrhage.

Authors:  Pu Zhao Wu; Jun Zhou; Yue Wei Zhang
Journal:  Exp Ther Med       Date:  2016-08-04       Impact factor: 2.447

8.  Spontaneous rupture of metastatic alpha-fetoprotein-producing gastric cancer of the liver.

Authors:  Tetsuro Sohda; Takayuki Hanano; Hisanori Miyamoto; Yoko Kitano; Kaoru Iwata; Masanori Yokoyama; Makoto Irie; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka
Journal:  Hepatol Int       Date:  2008-04-08       Impact factor: 6.047

9.  Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization.

Authors:  Song Gao; Ren-Jie Yang; Jia-Hong Dong
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

10.  Hemorrhagic ascites. Clinical presentation and outcomes in patients with cirrhosis.

Authors:  Nathalie H Urrunaga; Amit G Singal; Jennifer A Cuthbert; Don C Rockey
Journal:  J Hepatol       Date:  2013-01-21       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.